Search Results for “immune” – Page 65 – media

Making young mice old in a matter of three weeks

In a paper recently published in PNAS Nexus, researchers from the Department of Comparative Biosciences at the University of Illinois Urbana-Champaign describe how they were able to inhibit the activity of a specific neuronal cell type in the hippocampus to induce cellular and behavioral changes associated with aging. Their study confirms a causal relationship between reduced function of certain interneurons in the brain and cognitive decline. In addition, their novel experimental model may be useful for studying age-related cognitive disorders. First author Jinrui Lyu, a graduate student in the Neuroscience Program and the Department of Comparative Biosciences, performed and analyzed the experiments for the study. Corresponding author Uwe Rudolph is professor and head of the Department of Comparative Biosciences in the College of Veterinary Medicine. These authors answered some questions about the design and significance of their study. What was the motivation for your study? Our lab is interested in why ...
- Source: drugdu
- 121
- April 29, 2023
Amphera and Alligator Bioscience reveal mitazalimab-MesoPher update

Therapy is being used during pivotal phase 1 study into patients with pancreatic cancer Alligator Bioscience and Amphera have announced that the last patient in their REACTIVE-2 phase 1 research has been dosed. The research is evaluating mitazalimab when used in combination with MesoPher among patients with metastatic pancreatic cancer. The single location, open-label trial is assessing the efficacy and safety of Alligator’s lead candidate mitazalimab along with Amphera’s cancer vaccine MesoPher. It involves patients who have already undergone standard of care treatment with mFOLFIRINOX. The REACTIVE-2 study is currently being performed at Erasmus Medical Center in Rotterdam, the Netherlands, while initial results are expected later this year. Søren Bregenholt, chief executive officer at Alligator Bioscience, reflected: “Our CD40 agonist and Amphera’s cancer vaccine have both shown great promise in their own separate clinical studies emphasising the crucial role of dendritic cells and other myeloid cells in immune response to ...
- Source: drugdu
- 129
- April 29, 2023
Immunotherapy strongly improves prognosis of babies with leukemia

Immunotherapy with blinatumomab leads to a strongly improved survival rate—from 66% to 93%—for children with an aggressive form of acute lymphoblastic leukemia (ALL). They also had fewer side effects from the treatment. Based on the results, blinatumomab will now become standard treatment worldwide for babies with this aggressive form of leukemia. Three quarters of babies with acute lymphoblastic leukemia (ALL)—three babies a year in the Netherlands—have a particular fault in the DNA of their leukemia cells. This so-called KMT2A rearrangement leads to an aggressive form of ALL with a poor prognosis. Despite intensifying chemotherapy, the prognosis for these babies has not improved in recent decades. Intensive chemotherapy works very well for half of the babies. But in the other half of the children, the disease returned within two years, or children died from the disease or sometimes from the side effects of the therapy. 90% of recurrences—when the cancer comes ...
- Source: drugdu
- 138
- April 28, 2023
Orbital raises $270 million in biotech’s largest Series A round this year

Gwendolyn Wu Reporter Biotechnology venture firms have become more selective about where to invest in recent months, wary of the headwinds currently blowing against the industry. But that newfound caution hasn’t hurt Orbital Therapeutics, which said Wednesday it raised $270 million in biotech’s largest Series A round this year. The funds will help Orbital, which emerged from stealth last year partnered with gene editing pioneer Beam Therapeutics, to build its team and select a lead program. It claims its technology could be applied in many different directions, from use in next-generation RNA vaccines to protein replacement therapies or drugs for autoimmune diseases and cancer. Based in Cambridge, Massachusetts, Orbital has not yet named specific disease areas it’s prioritizing. However, the financing positions the company to submit its first regulatory filing, like an application to begin human testing, in the next two to four years, CEO Giuseppe Ciaramella said. “The ...
- Source: drugdu
- 225
- April 28, 2023
Study shows no significant cognitive benefit of adhering to Mediterranean diets regardless of calorie intake

In a recent study published in Preventive Medicine Reports Journal, researchers performed a randomized clinical trial (RCT) to investigate whether adhering to the Mediterranean diet (MedDiet) with or without limiting calorie intake could improve cognition. Background Obesity, lifestyle choices including diet and exercise, and cardiometabolic comorbidities elevate the risk of cognitive decline. To date, there are no efficient pharmaceutical therapeutics available to prevent, retard, or manage cognitive deficits. However, studies have shown that MedDiet and weight loss benefit cognition, and combining the two may enhance cognitive function. However, RCTs have shown inconsistent results, with either a favorable or negligible impact of nutrition on cognition, warranting further research. About the study In the present three-arm RCT, researchers evaluated the potential cognitive benefit of adhering to MedDiet with or without limiting calorie intake. The Building Research in Diet and Cognition study was conducted between January 2017 and ...
- Source: drugdu
- 133
- April 27, 2023
Drugmakers take sides in Amgen, Regeneron fight over antibody patents

Christopher Newman Editor “This is a showdown about whether the most valuable patents in the entirety of the patent system are valid,” one law expert said. The nearly decade-long patent feud between Amgen and rivals Sanofi and Regeneron has divided the biopharmaceutical industry, with drugmakers taking different sides in a U.S. Supreme Court case that could have far-reaching effects. At issue are patents for powerful cholesterol-lowering medicines known as PCSK9 inhibitors. Regeneron and Sanofi brought the first, Praluent, to market in 2015. Amgen followed one month later with a similar medicine, called Repatha. The drugs work by boosting liver cells’ ability to hoover up LDL, or “bad,” cholesterol. Amgen has long claimed Sanofi and Regeneron infringed on patents it secured for Praluent. The fight has slowly winded its way through the U.S. legal system to reach the Supreme Court. There, judges could disrupt the $160 billion-per-year market for antibodies by deciding how broadly ...
- Source: drugdu
- 171
- April 25, 2023
How alcohol consumption contributes to chronic pain

Chronic alcohol consumption may make people more sensitive to pain through two different molecular mechanisms—one driven by alcohol intake and one by alcohol withdrawal. That is one new conclusion by scientists at Scripps Research on the complex links between alcohol and pain. The research, published in the British Journal of Pharmacology on April 12, 2023, also suggests potential new drug targets for treating alcohol-associated chronic pain and hypersensitivity. “There is an urgent need to better understand the two-way street between chronic pain and alcohol dependence,” says senior author Marisa Roberto, Ph.D., the Schimmel Family Chair of Molecular Medicine, and a professor of neuroscience at Scripps Research. “Pain is both a widespread symptom in patients suffering from alcohol dependence, as well as a reason why people are driven to drink again.” Alcohol use disorder (AUD), which encompasses the conditions commonly called alcohol abuse, alcohol dependence and alcohol addiction, ...
- Source: drugdu
- 120
- April 25, 2023
New injectable cell therapy could resolve osteoarthritis

Wake Forest Institute for Regenerative Medicine (WFIRM) scientists have created a promising injectable cell therapy to treat osteoarthritis that both reduces inflammation and also regenerates articular cartilage. Recently identified by the Food and Drug Administration as a public health crisis, osteoarthritis affects more than 520 million people worldwide who deal with pain and inflammation. Osteoarthritis is typically induced by mechanical or traumatic stress in the joint, leading to damaged cartilage that cannot be repaired naturally. “Without better understanding of what drives the initiation and progression of osteoarthritis, effective treatment has been limited,” said lead author Johanna Bolander of WFIRM. “Initially, we studied what goes wrong in osteoarthritic joints, compared these processes to functional environments, and used this information to develop an immunotherapy cell treatment.” Osteoarthritis is a disease of the joint system. The joint includes a synovial membrane—a connective tissue that lines the inner surface of the joint. The membrane functions to protect the joint ...
- Source: drugdu
- 120
- April 25, 2023
J&J study data show dramatic benefit to multiple myeloma cell therapy

A study abstract inadvertently posted online showed J&J and Legend’s therapy, Carvykti, reduced the risk of disease progression or death by more than 70% over standard drugs. The cancer cell therapy Carvykti dramatically outperformed standard drugs in a late-stage clinical trial testing its use in earlier treatment of the blood cancer multiple myeloma, according to data from a study abstract that was briefly posted online Tuesday. The abstract showed Carvykti, which is made by Johnson & Johnson and Legend Biotech, reduced the risk of disease progression or death by 74% compared to standard of care — a degree of benefit that analysts who viewed it described as “stellar” and “highly encouraging.” J&J and Legend had previously said in late January that the study met its main goal, but did not disclose any specific data at the time. The abstract, which is no longer available online, was for presentation ...
- Source: drugdu
- 114
- April 20, 2023
CDC signs off on additional Covid-19 booster doses for certain people

The US Centers for Disease Control and Prevention updated its recommendations on the Covid-19 vaccines on Wednesday to allow another dose of the bivalent booster for people who are 65 and older or who have weakened immune systems and who “want the option of added protection” against the coronavirus. The move aligns with Tuesday’s US Food and Drug Administration actions to allow these groups to get additional booster doses ahead of the fall vaccination campaign. On Wednesday, members of CDC’s Advisory Committee for Immunization Practices met to discuss the changes and expressed their support for them, although the committee did not vote. Monovalent mRNA vaccines, which protect only against the original strain of the coronavirus, will no longer be recommended in the United States, the CDC says. The updated bivalent shots from Moderna and Pfizer/BioNTech protect against the original strain as well as the BA.4 and BA.5 subvariants ...
- Source: drugdu
- 106
- April 20, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.